WuXi Biologics (Cayman) Inc
1FW2
Company Profile
Business description
WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.
Contact
No. 108, Meiliang Road
Mashan Binhu District
Wuxi214092
CHNT: +86 51085353482
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
12,575
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
SiteMinder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks
Impact of ANZ’s huge fine
Working to prevent repeated failures could also improve competitiveness.
stocks
Acquisition a sign of weakness for overvalued ASX share
Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,094.90 | 27.60 | -0.30% |
| CAC 40 | 7,786.98 | 31.24 | -0.40% |
| DAX 40 | 23,359.18 | 29.94 | 0.13% |
| Dow JONES (US) | 46,199.19 | 441.29 | 0.96% |
| FTSE 100 | 9,208.37 | 12.71 | 0.14% |
| HKSE | 26,908.39 | 469.88 | 1.78% |
| NASDAQ | 22,241.95 | 92.01 | -0.41% |
| Nikkei 225 | 44,790.38 | 111.89 | -0.25% |
| NZX 50 Index | 13,228.38 | 6.51 | -0.05% |
| S&P 500 | 6,609.16 | 2.40 | 0.04% |
| S&P/ASX 200 | 8,818.50 | 30.00 | -0.34% |
| SSE Composite Index | 3,876.34 | 14.48 | 0.37% |